1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Who are their customers?

Discussion in 'Epocrates' started by Anonymous, Aug 24, 2010 at 7:10 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    ...and what do they REALLY do?
     

  2. Anonymous

    Anonymous Guest

    All I know is they came in here and most everyone was WAY underwhelmed. Maybe it was just the folks that presented but I found zero value.
     
  3. Anonymous

    Anonymous Guest

    CEO leaves soon after IPO

    What happen there? Did she get the heave ho?
     
  4. Anonymous

    Anonymous Guest

    Rose

    Booted out on her can!
     
  5. Anonymous

    Anonymous Guest

    thats the third executive to leave or shown the door in the past few months; what gives?
     
  6. Anonymous

    Anonymous Guest

    A company hopelessly lost with little to no strategic vision. Rose was given a poor poker hand and was unable to draw any new cards. She will go down as another leader from Pharma who could not cut it in the small company world.
     
  7. Anonymous

    Anonymous Guest

    C suite is a revolving door. Full turnover on all C positions x3 or so for the past three years. The board is now trying a bunch of CareFX retreads. Revenue stagnant, so cost cuts will make the numbers.